---
title: "Odyssey Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294811170.md"
datetime: "2026-08-04T11:02:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294811170.md)
  - [en](https://longbridge.com/en/news/294811170.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294811170.md)
---

# Odyssey Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EBIT: As of FY2026 Q2, the actual value is USD -52.8 M.

### Financial Results for Q2 2026

#### Cash Position

As of June 30, 2026, Odyssey Therapeutics, Inc. reported cash, cash equivalents, and marketable securities of $433.1 million, which is projected to fund operations into the second half of 2028.

#### Research and Development Expenses

Research and development expenses for the quarter ended June 30, 2026, totaled $36.2 million, an increase from $30.2 million in the same period of 2025, primarily due to higher external research and development costs for advancing clinical and preclinical programs.

#### General and Administrative Expenses

General and administrative expenses decreased to $10.5 million for the quarter ended June 30, 2026, compared to $13.2 million for the same period in 2025, mainly reflecting lower legal and accounting professional fees.

#### Net Loss

Odyssey Therapeutics, Inc. reported a net loss of - $52.8 million for the quarter ended June 30, 2026, which is higher than the net loss of - $41.2 million for the corresponding period in 2025.

#### Adjusted Net Loss (Non-GAAP)

Adjusted net loss (non-GAAP) was - $38.4 million for the quarter ended June 30, 2026, compared to - $38.1 million for the same period in 2025. The adjusted net loss for Q2 2026 excludes $8.7 million in non-cash charges related to the change in the fair value of contingent consideration and $5.7 million in stock-based compensation expense. For Q2 2025, it excluded - $0.6 million for change in fair value of contingent consideration and $3.7 million for stock-based compensation expense.

### Operational Outlook and Milestones

Odyssey Therapeutics, Inc. anticipates presenting Phase 2a OD-001 data in October and initiating two new OD-001 trials in the second half of 2026, with topline data expected in the second half of 2027. For OD-002, the company plans to complete IND-enabling studies and file a CTA in the second half of 2026, targeting a Phase 1/2a trial initiation in the first half of 2027.

### Related Stocks

- [ODTX.US](https://longbridge.com/en/quote/ODTX.US.md)

## Related News & Research

- [FN: Record revenue and EPS growth in Q4 and FY26, with strong outlook for Q1 FY27](https://longbridge.com/en/news/296142824.md)
- [Boa Safra board signs off on Q2 2026 interim financial statements through June 30](https://longbridge.com/en/news/295986061.md)
- [Vital Farms amends 8-K to add missing Item 5.03 in EDGAR header](https://longbridge.com/en/news/296122466.md)
- [MRCY: Record bookings, backlog, and revenue drive improved outlook and strong FY26 performance](https://longbridge.com/en/news/296265272.md)
- [JKHY: Record revenue and margin growth in 2026, with strong outlook for 2027](https://longbridge.com/en/news/296268676.md)